Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Javeroic acid is a lanostane-type triterpenoid isolated from the medicinal mushroom *Fuscoporia torulosa* (formerly known as *Phellinus torulosus*). Chemically identified as 3-oxolanosta-8,24-dien-21-oic acid, it is one of several bioactive secondary metabolites that contribute to the pharmacological profile of this mushroom. Javeroic acid and related triterpenes from *F. torulosa* have been investigated in preclinical research for their potential therapeutic properties, including cytotoxic activity against human cancer cell lines such as MCF-7 (breast cancer) and PC-3 (prostate cancer). Additionally, extracts containing javeroic acid have demonstrated inhibitory effects on enzymes such as acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and tyrosinase, suggesting potential applications in the treatment of neurodegenerative disorders and skin hyperpigmentation. It also exhibits antioxidant capacity, which may provide protective effects against oxidative stress-related cellular damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on javeroic acid.